ESR1 and breast cancer: These results indicate that the subgroup of ERα-positive breast cancer patients comprising CAFs with low pERK level are linked to an impaired tamoxifen response despite having ERα-positive breast cancer cells whereas SMAα level in CAFs is not predictive for tamoxifen response.